https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Exercise-Induced Left Atrial Hypertension in Heart Failure With Preserved Ejection Fraction https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51281 Wed 30 Aug 2023 09:59:56 AEST ]]> Established and Emerging Cancer Therapies and Cardiovascular System: Focus on Hypertension - Mechanisms and Mitigation https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52384 Wed 28 Feb 2024 15:35:45 AEDT ]]> Elevated Soluble Suppressor of Tumorigenicity 2 Predict Hospital Admissions Due to Major Adverse Cardiovascular Events (MACE) https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53520 28.4 ng/mL) was independently associated with older age, use of beta-blockers, and number of MACE events within a 1 year period. In this patient cohort, elevated sST2 levels are associated with unplanned hospital admission due to MACE within 1 year, independent of the nature of the index cardiovascular admission.]]> Wed 28 Feb 2024 15:31:59 AEDT ]]> Patient characteristics, short-term and long-term outcomes after incident heart failure admissions in a regional Australian setting https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52044 Wed 27 Sep 2023 10:07:51 AEST ]]> Factors associated with adverse cardiovascular events in cancer patients treated with bevacizumab https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45109 n = 230 patients (mean age 65, males n = 124 (53.9%)) were treated with bevacizumab during the study period. N = 28 patients were admitted to hospital for a major cardiovascular-related event. Higher total treatment dose (p < 0.05), concomitant hypertension (p = 0.005), diabetes (p = 0.04), atrial fibrillation (p = 0.03), and lack of use of statin therapy (p = 0.03) were key contributors to hospital admission. Conclusions: Results of our study highlight the fact that patients with concomitant baseline cardiovascular disease/risk factors are at an increased risk of cardiovascular hospitalization related to bevacizumab treatment. Careful baseline cardiovascular assessment may be an essential step to minimize cardiovascular complications.]]> Wed 26 Oct 2022 13:22:56 AEDT ]]> Nexus of cancer and cardiovascular disease for Australia's first peoples https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45068 Wed 26 Oct 2022 12:31:21 AEDT ]]> International consensus statement on the management of cardiovascular risk of Bruton’s tyrosine kinase inhibitors in CLL https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52741 Wed 25 Oct 2023 08:41:19 AEDT ]]> Decreased ATP production and myocardial contractile reserve in metabolic heart disease https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33017 ~ATP), c) the rate of ATP production and d) flux through the creatine kinase (CK) reaction. At the lowest workload, the diastolic pressure-volume relationship was shifted upward in HFHS hearts, indicative of diastolic dysfunction, whereas systolic function was preserved. At this workload, the rate of ATP synthesis was decreased in HFHS hearts, and was associated with decreases in both [PCr] and ΔG~ATP. Higher work demands unmasked the inability of HFHS hearts to increase systolic function and led to a further decrease in ΔG~ATP to a level that is not sufficient to maintain normal function of sarcoplasmic Ca²⁺-ATPase (SERCA). While [ATP] was preserved at all work demands in HFHS hearts, the progressive increase in [ADP] led to a decrease in ΔG~ATP with increased work demands. Surprisingly, CK flux, CK activity and total creatine were normal in HFHS hearts. These findings differ from dilated cardiomyopathy, in which the energetic deficiency is associated with decreases in CK flux, CK activity and total creatine. Thus, in HFHS-fed mice with MHD there is a distinct metabolic phenotype of the heart characterized by a decrease in ATP production that leads to a functionally-important energetic deficiency and an elevation of [ADP], with preservation of CK flux.]]> Wed 24 Nov 2021 15:52:41 AEDT ]]> Increased risk of atrial fibrillation among patients undergoing coronary artery bypass graft surgery while receiving nitrates and antiplatelet agents https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33411 Wed 19 Jan 2022 15:18:12 AEDT ]]> The Importance of Primary Care in Cardio-Oncology https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48902 Wed 19 Apr 2023 16:30:23 AEST ]]> Early access to a cardio-oncology clinic in an Australian context: a qualitative exploration of patient experiences https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53423 Wed 17 Apr 2024 14:39:15 AEST ]]> Patterns of contraceptive use among young Australian women with chronic disease: findings from a prospective cohort study https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51034 Wed 16 Aug 2023 10:16:36 AEST ]]> Global Cardio Oncology Registry (G-COR): Registry Design, Primary Objectives, and Future Perspectives of a Multicenter Global Initiative https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54028 Wed 13 Mar 2024 07:47:53 AEDT ]]> Preparation for cardiac procedures: a cross-sectional study identifying gaps between outpatients' views and experiences of patient-centred care https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:55657 80% of participants as essential. Of those, for 22 items, <80% reported the care as received. Gaps were identified in relation to GP consultation (1 item), preparation (1 item) subsequent decision making for treatment (1 item), prognosis (6 items) and post-treatment follow-up (1 item). Conclusions: Areas were identified where actual care fell short of patients' perceptions of essential care.]]> Wed 12 Jun 2024 10:07:58 AEST ]]> Fibulin-3 is necessary to prevent cardiac rupture following myocardial infarction https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52438 Wed 11 Oct 2023 14:53:58 AEDT ]]> Heart failure outcomes in Aboriginal and Torres Strait Islander peoples in the Hunter New England region of New South Wales https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49072 Wed 03 May 2023 16:08:08 AEST ]]> Remote monitoring in patients with heart failure with cardiac implantable electronic devices: A systematic review and meta-analysis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48120 Wed 01 Mar 2023 15:36:11 AEDT ]]> Suboptimal Use of Cardioprotective Medications in Patients With a History of Cancer https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:42651 Wed 01 Mar 2023 15:00:54 AEDT ]]> Overexpression of Mitochondrial Catalase within Adipose Tissue Does Not Confer Systemic Metabolic Protection against Diet-Induced Obesity https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52575 Tue 17 Oct 2023 15:48:02 AEDT ]]> Pulmonary Hypertension Due to Left Heart Disease https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41950 20 mm Hg and pulmonary capillary wedge pressure >15 mm Hg during right heart catheterization. LHD may lead to elevated left atrial pressure alone, which in the absence of intrinsic pulmonary vascular disease will result in PH without changes in pulmonary vascular resistance. Persistent elevation in left atrial pressure may, however, also be associated with subsequent pulmonary vascular remodeling, vasoconstriction, and an increase in pulmonary vascular resistance. Hence, there are 2 subgroups of PH due to LHD, isolated postcapillary PH and combined post- and precapillary PH, with these groups have differing clinical implications. Differentiation of pulmonary arterial hypertension and PH due to LHD is critical to guide management planning; however, this may be challenging. Older patients, patients with metabolic syndrome, and patients with imaging and clinical features consistent with left ventricular dysfunction are suggestive of LHD etiology rather than pulmonary arterial hypertension. Hemodynamic measures such as diastolic pressure gradient, transpulmonary gradient, and pulmonary vascular resistance may assist to differentiate pre- from postcapillary PH and offer prognostic insights. However, these are influenced by fluid status and heart failure treatment. Pulmonary arterial hypertension therapies have been trialed in the treatment with concerning results reflecting disease heterogeneity, variation in inclusion criteria, and mixed end point criteria. The aim of this review is to provide an updated definition, discuss possible pathophysiology, clinical aspects, and the available treatment options for PH due to LHD.]]> Tue 16 Aug 2022 14:31:43 AEST ]]> Energetic dysfunction is mediated by mitochondrial reactive oxygen species and precedes structural remodeling in metabolic heart disease https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48338 per se, is sufficient to cause contractile dysfunction in MHD.]]> Tue 14 Mar 2023 17:22:37 AEDT ]]> The role of pathological aging in cardiac and pulmonary fibrosis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44253 Tue 11 Oct 2022 12:28:35 AEDT ]]> Integrating CardioOncology Across the Research Pipeline, Policy, and Practice in Australia-An Australian Cardiovascular Alliance Perspective https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:55631 Tue 11 Jun 2024 18:36:59 AEST ]]> Ibrutinib-related atrial fibrillation: a single center Australian experience https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46897 Tue 06 Dec 2022 13:41:57 AEDT ]]> Sex-based differences in short- and longer-term diet-induced metabolic heart disease https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:55437 Thu 30 May 2024 14:32:42 AEST ]]> Outcomes following heart failure hospitalization in a regional Australian setting between 2005 and 2014 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:43342 Thu 15 Sep 2022 15:18:47 AEST ]]> Cardiovascular outcomes of cancer patients in rural Australia https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51481 Thu 07 Sep 2023 10:51:46 AEST ]]> Mind The Gap, Aboriginal and Torres Strait Islander Cardiovascular Health: A Narrative Review https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53262 Mon 20 Nov 2023 12:14:02 AEDT ]]> Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44599 Mon 17 Oct 2022 16:08:38 AEDT ]]> Management of Acute Coronary Syndromes in Patients in Rural Australia: The MORACS Randomized Clinical Trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50968 Mon 14 Aug 2023 15:20:39 AEST ]]> Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47964 70 mm Hg associated with worse outcomes]), right atrial volume index (pinteraction=0·012 [≥29·7 mL/m2, worse outcomes]), and sex (pinteraction=0·02 [men, worse outcomes]). There were no differences in the composite safety endpoint between the two groups (n=116 [38%] for shunt device vs n=97 [31%] for sham procedure; p=0·11). Interpretation: Placement of an atrial shunt device did not reduce the total rate of heart failure events or improve health status in the overall population of patients with heart failure and ejection fraction of greater than or equal to 40%. Funding: Corvia Medical.]]> Mon 13 Feb 2023 15:45:01 AEDT ]]> Association of Circulating Plasma Secreted Frizzled-Related Protein 5 (Sfrp5) Levels with Cardiac Function https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52280 Mon 09 Oct 2023 10:02:50 AEDT ]]> Obesity in heart failure with preserved ejection fraction: Insights from the REDUCE LAP-HF II trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54596 Mon 04 Mar 2024 08:42:35 AEDT ]]> Oxidative modifications of mitochondrial complex II are associated with insulin resistance of visceral fat in obesity https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:42207 2) during planned bariatric surgery. Compared with subcutaneous adipose tissue, visceral adipose tissue exhibited decreased complex II activity, which was restored with the reducing agent dithiothreitol (5 mM) (P < 0.01). A biotin switch assay identified that cysteine oxidative posttranslational modifications (OPTM) in complex II subunit A (succinate dehydrogenase A) were increased in visceral vs. subcutaneous fat (P < 0.05). Insulin treatment (100 nM) stimulated complex II activity in subcutaneous fat (P < 0.05). In contrast, insulin treatment of visceral fat led to a decrease in complex II activity (P < 0.01), which was restored with addition of the mitochondria-specific oxidant scavenger mito-TEMPO (10 µM). In a cohort of 10 subjects with severe obesity, surgical weight loss decreased OPTM and restored complex II activity, exclusively in the visceral depot. Mitochondrial complex II may be an unrecognized and novel mediator of insulin resistance associated with visceral adiposity. The activity of complex II is improved by weight loss, which may contribute to metabolic improvements associated with bariatric surgery.]]> Fri 26 Aug 2022 09:16:37 AEST ]]> Heart Failure in Breast Cancer Survivors: Focus on Early Detection and Novel Biomarkers https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48913 Fri 14 Apr 2023 18:21:40 AEST ]]>